Reliability and Validity of the French Version of the Virtual Reality Sickness Questionnaire (VRSQ-F)
May 26, 2025 updated by: Pôle Saint Hélier
This is a multicenter, controlled, non-randomized interventional clinical study, with minimal risks and constraints, aimed at verifying the reliability of the French version of the VRSQ questionnaire (VRSQ-F) and the validity of the VRSQ-F score by comparing it with the SSQ score.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier, France, 34090
- Centre de Rééducation Fonctionnelle Neurologique PROPARA
-
Rennes, France
- Pôle Saint-Hélier
-
Roscoff, France, 29684
- Fondation Ildys
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
For Healthy people :
- Men or women aged 18 to 65
- Person affiliated to a social security scheme
- Healthy person with no particular medical condition
- Having given their consent to participate in the research
For patients :
- Men or women aged 18 to 65
- Persons affiliated to a social security scheme
- People undergoing regular rehabilitation, walking or in a wheelchair, who can use a virtual reality solution as part of their care.
- Having given their consent to take part in the research
Exclusion Criteria:
- Vestibular and cardiac pathologies, and major visual disorders not compatible with virtual reality rehabilitation
- Cognitive and language disorders
- Persons under legal protection
- Pregnant women
- MSSQ greater than 15
- People suffering from photosensitive epilepsy
- Persons under the influence of medication that may impair drugs or alcohol
- Participant with an implanted medical device that may be affected by radio waves emitted by compatible third-party equipment (e.g. : Pacemaker)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Single Group
Participants will be asked to use the measurement instrument VRSQ-F on two separate occasions under identical conditions to assess its test-retest reliability and asked to use the SSQ for validity.
Each session will involve completing the measurement protocol as specified.
|
Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions.
The results from both sessions will be compared to assess the instrument's consistency and accuracy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Check the validity of the VRSQ-F score by comparing it with the SSQ score
Time Frame: Immediately after exercises
|
Criteria validity between SSQ and VRSQ-F.
SSQ questionnaire with 16 questions scoring from 0 to 48 VRSQ-F questionnaire with 9 questions from 0 to 27
|
Immediately after exercises
|
|
Reliability of VRSQ-F (Virtual Reality Sickness Questionnaire) using the intraclass correlation coefficient between measurements immediately after VR exercises and 15 min after and Cronbach coefficient of the VRSQ-F questionnaire
Time Frame: Immediately after exercises
|
Reliability of VRSQ-F (Virtual Reality Sickness Questionnaire) using the intraclass correlation coefficient between measurements immediately after VR exercises and 15 min after and Cronbach coefficient of the VRSQ-F questionnaire
|
Immediately after exercises
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calculate the minimum detectable change in the questionnaire
Time Frame: Immediately after exercises
|
Clinimetric quality: Calculation of the standard error of measurement SEM and the minimum detectable change MDC
|
Immediately after exercises
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Emilie LEBLONG, Pole Saint Helier
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2024
Primary Completion (Actual)
May 14, 2025
Study Completion (Actual)
May 14, 2025
Study Registration Dates
First Submitted
June 7, 2024
First Submitted That Met QC Criteria
June 13, 2024
First Posted (Actual)
June 20, 2024
Study Record Updates
Last Update Posted (Actual)
May 28, 2025
Last Update Submitted That Met QC Criteria
May 26, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2023-A02468-37
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.